Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind,…

By C. Moskowitz, A. Nademanee, T. Masszi, E. Agura, J. Hołowiecki, M. Abidi, Andy I. Chen, P. Stiff, A. Gianni, A. Carella and 10 more. The Lancet, 2015

671 citations recorded by the source corpus.

Subfields: Dermatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/279156b3f2e6606fad806419d903856d0a8509e4

Citations in the corpus

• Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. (2017, neutral): “(%) 4 (2-12) 4 (1-11) 3 (2-10) 4 (1-12) Prior lines of therapy, No.”